Michał Suchecki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michał Suchecki has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adriana M. Paskal
Department of Methodology, Medical University of Warsaw, 1b Banacha Street, 02-091 Warsaw, Poland
1 shared publication - Antoni Smoliński
Department of Methodology, Medical University of Warsaw, 1b Banacha Street, 02-091 Warsaw, Poland
1 shared publication - Mateusz Gotowiec
Department of Methodology, Medical University of Warsaw, 1b Banacha Street, 02-091 Warsaw, Poland
1 shared publication - Michał Kopka
Department of Methodology, Medical University of Warsaw, 1b Banacha Street, 02-091 Warsaw, Poland
1 shared publication - Paweł Włodarski
Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland
1 shared publication - Wiktor Paskal
Department of Methodology, Medical University of Warsaw, 1b Banacha Street, 02-091 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 25 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10330
Biologic Brachytherapy: Genetically Modified Surgical Flap as a Therapeutic Tool—A Systematic Review of Animal Studies
Surgical flaps are rudimentary tools in reconstructive surgery, especially following extensive solid tumour resections. They cover skin and soft tissue defects but are prone to ischaemia and necrosis. Since their primary aim is reconstruction, they rarely exhibit a therapeutic activity against the treated disease. Attempts have been made to develop a new therapeutic strategy—biologic brachytherapy, which uses genetically engineered surgical flaps as a drug delivery vehicle, allowing the flap tissue to act as a “biologic pump”. This systematic review summarizes the preclinical evidence on using genetically modified surgical flaps. A literature search was conducted in PubMed, EMBASE, Scopus and Web of Science. The initial literature search yielded 714 papers, and, eventually, seventy-seven studies were included in qualitative analysis. The results show that genetic enhancement of flaps has been used as a local or systemic therapy for numerous disease models. Frequently, it has been used to increase flap survival and limit ischaemia or promote flap survival in a non-ischemic context, with some studies focusing on optimizing the technique of such gene therapy. The results show that genetically modified flaps can be successfully used in a variety of contexts, but we need more studies to implement this research into specific clinical scenarios.
- 25 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10330
Open AccessBiologic Brachytherapy: Genetically Modified Surgical Flap as a Therapeutic Tool—A Systematic Review of Animal Studies
Surgical flaps are rudimentary tools in reconstructive surgery, especially following extensive solid tumour resections. They cover skin and soft tissue defects but are prone to ischaemia and necrosis. Since their primary aim is reconstruction, they rarely exhibit a therapeutic activity against the treated disease. Attempts have been made to develop a new therapeutic strategy—biologic brachytherapy, which uses genetically engineered surgical flaps as a drug delivery vehicle, allowing the flap tissue to act as a “biologic pump”. This systematic review summarizes the preclinical evidence on using genetically modified surgical flaps. A literature search was conducted in PubMed, EMBASE, Scopus and Web of Science. The initial literature search yielded 714 papers, and, eventually, seventy-seven studies were included in qualitative analysis. The results show that genetic enhancement of flaps has been used as a local or systemic therapy for numerous disease models. Frequently, it has been used to increase flap survival and limit ischaemia or promote flap survival in a non-ischemic context, with some studies focusing on optimizing the technique of such gene therapy. The results show that genetically modified flaps can be successfully used in a variety of contexts, but we need more studies to implement this research into specific clinical scenarios.